GlobeNewswire
- Home
- APLT
as of 12-12-2025 4:00pm EST
$0.12
$0.10
-45.50%
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Chart Type:
Time Range:
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 38.1M | IPO Year: | 2019 |
| Target Price: | $1.25 | AVG Volume (30 days): | 27.2M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.11 - $1.50 | Next Earning Date: | 11-13-2025 |
| Revenue: | $1,000,000 | Revenue Growth: | -95.45% |
| Revenue Growth (this year): | 124.18% | Revenue Growth (next year): | 66.67% |
AI-Powered APLT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 68.63%
68.63%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Applied Therapeutics Inc. News
APLT Breaking Stock News: Dive into APLT Ticker-Specific Updates for Smart Investing
Compare APLT vs Leading Stocks
See how APLT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APLT Applied Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.